Aprea Therapeutics Profit Margin

Aprea Therapeutics (APRE) currently reports a profit margin of -9843.58% as of March 2026. That compares with -1834.95% in the prior-year period — down 436.4% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Aprea Therapeutics's profit margin history and peer comparisons.

Aprea Therapeutics's profit margin decreased from -1834.95% to -9843.58% — a 436.4% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aprea Therapeutics's profit margin of -9843.58% is lower than the Healthcare sector average of 14.34%. That is roughly 68721.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Aprea Therapeutics's current -9843.58% should be judged against Healthcare norms (sector average: 14.34%) and against APRE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -9843.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Aprea Therapeutics, and consider following APRE for alerts when major investors trade the stock.